These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22488017)

  • 1. Response criteria can be misleading when drawing conclusion regarding neoadjuvant chemotherapy in advanced ovarian cancer.
    Bellati F; Gasparri ML; Caccetta J; Palaia I; Benedetti panici P
    J Surg Oncol; 2012 Sep; 106(4):529; author reply 527-8. PubMed ID: 22488017
    [No Abstract]   [Full Text] [Related]  

  • 2. The predictors of response to neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yildirim Y; Ertas IE; Dogan A; Gultekin OE; Gultekin E
    J Surg Oncol; 2012 Feb; 105(2):200-5. PubMed ID: 21815151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laparoscopic Debulking Surgery in the Management of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy.
    Corrado G; Mancini E; Cutillo G; Baiocco E; Vici P; Sergi D; Patrizi L; Saltari M; Baffa A; Vizza E
    Int J Gynecol Cancer; 2015 Sep; 25(7):1253-7. PubMed ID: 26111273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.
    Ren Y; Shi T; Jiang R; Yin S; Wang P; Zang R
    Int J Gynecol Cancer; 2015 Oct; 25(8):1398-404. PubMed ID: 26222486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.
    Grivas A; Lianos E; Internos I; Papaxoinis G; Tselepatiotis E; Ziras N; Athanasiou AE
    J BUON; 2010; 15(4):647-51. PubMed ID: 21229624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of diaphragmatic surgery during interval debulking after neoadjuvant chemotherapy: an analysis of 74 patients with advanced epithelial ovarian cancer.
    Tsolakidis D; Amant F; Van Gorp T; Leunen K; Neven P; Vergote I
    Int J Gynecol Cancer; 2010 May; 20(4):542-51. PubMed ID: 20686373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
    Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
    Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of Epithelial Ovarian Cancer: Time for Strategy Trials to Resolve the Problem of Optimal Timing of Surgery.
    Van de Putte G; Oben J; Prenen L; Schobbens JC; Vlasselaer J; Van Holsbeke C; Debrock G; Van Eycken P; de Jonge E
    Int J Gynecol Cancer; 2015 Jul; 25(6):993-9. PubMed ID: 25914962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
    Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
    Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
    Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
    Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should all patients with serous and clear cell endometrial carcinoma receive adjuvant chemotherapy?
    Boren TP; Miller DS
    Womens Health (Lond); 2010 Nov; 6(6):789-95. PubMed ID: 21118038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer.
    Aletti GD; Nordquist D; Hartmann L; Gallenberg M; Long HJ; Cliby WA
    Ann Oncol; 2010 Sep; 21(9):1772-1778. PubMed ID: 20139154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphologic changes in ovarian carcinoma after neoadjuvant chemotherapy: report of a case showing extensive clear cell changes mimicking clear cell carcinoma.
    Chew I; Soslow RA; Park KJ
    Int J Gynecol Pathol; 2009 Sep; 28(5):442-6. PubMed ID: 19696613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of hospitalizations associated with adverse effects of chemotherapy in a large community-based cohort of elderly women with ovarian cancer.
    Nurgalieva Z; Liu CC; Du XL
    Int J Gynecol Cancer; 2009 Nov; 19(8):1314-21. PubMed ID: 20009883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma.
    Aoki D; Katsumata N; Nakanishi T; Kigawa J; Fujiwara K; Takehara K; Kamiura S; Hiura M; Hatae M; Sugiyama T; Ochiai K; Noda K
    Jpn J Clin Oncol; 2011 Mar; 41(3):320-7. PubMed ID: 20974678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
    Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP
    Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian cancer treatments on the horizon.
    Schmidt C
    J Natl Cancer Inst; 2011 Sep; 103(17):1284-5. PubMed ID: 21852261
    [No Abstract]   [Full Text] [Related]  

  • 19. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
    Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O
    Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in Ki-67 labeling indices during neoadjuvant chemotherapy for advanced ovarian cancer are associated with survival.
    Pölcher M; Friedrichs N; Rudlowski C; Fimmers R; Keyver-Paik MD; Kübler K; Sauerwald A; Büttner R; Kuhn W; Braun M
    Int J Gynecol Cancer; 2010 May; 20(4):555-60. PubMed ID: 20442588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.